BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Johnson and Johnson

Below is an extended Johnson and Johnson research listing. Click here to return to the Johnson and Johnson main Biocorporate entry.

Recent Publications by Johnson and Johnson:

Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor.
The TRPA1 channel is activated by a number of pungent chemicals, such as...
25th September, 2008
Department of Neuroscience, Johnson and Johnson Pharmaceutical Research Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6. Epub 2008 Apr 20.
DOI Direct Link
A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.
The purpose of this analysis was the development of an IVIVC model, which...
10th September, 2008
Johnson and Johnson Pharmaceutical Research & Development, A Division of J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):423-41. Epub 2008 Sep 9.
DOI Direct Link
Cleaved SLPI, a novel biomarker of chymase activity.
Secretory leukocyte protease inhibitor (SLPI) is a protease inhibitor of...
21st August, 2008
Target Validation Team, Johnson and Johnson Pharmaceutical Research and Biol Chem. 2008 Sep;389(9):1219-24.
DOI Direct Link
Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death.
We have previously shown that Dz13, a catalytic DNA molecule (DNAzyme)...
14th August, 2008
Johnson and Johnson Research Pty Limited, Eveleigh, New South Wales, 1430, Oligonucleotides. 2008 Fall;18(3):257-68.
DOI Direct Link
Optimisation of the cell cultivation methods in the embryonic stem cell test results in an increased differentiation potential of the cells into strong beating myocard cells.
In order to support drug research in the selection process for...
2nd August, 2008
Johnson and Johnson Pharmaceutical Research and Development, A division of Toxicol In Vitro. 2008 Oct;22(7):1789-96. Epub 2008 Jul 11.
DOI Direct Link
Health insurance in China and India: segmented roles for public and private financing.
Surveys suggest that over the past five to ten years, the amount of health...
9th July, 2008
Johnson and Johnson Medical Asia Pacific, in New Delhi, India. Health Aff (Millwood). 2008 Jul-Aug;27(4):1005-15.
DOI Direct Link
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
Doripenem, a parenteral carbapenem, exhibited high affinity for...
4th July, 2008
Johnson and Johnson Pharmaceutical Research and Development, LLC, Room Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2. Epub 2008 Feb 4.
DOI Direct Link
A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry.
A need still exists for a liquid chromatography/tandem mass spectrometry...
11th June, 2008
Drug Metabolism and Pharmacokinetics, Global Preclinical Development, Rapid Commun Mass Spectrom. 2008 Apr;22(8):1295-311.
DOI Direct Link
Hsp27 regulates pro-inflammatory mediator release in keratinocytes by modulating NF-kappaB signaling.
Heat-shock protein 27 (Hsp27) is a member of the small Hsp family that...
20th May, 2008
Preclinical Pharmacology, Johnson and Johnson Skin Research Center, CPPW, J Invest Dermatol. 2008 May;128(5):1116-22. Epub 2007 Nov 15.
DOI Direct Link
Virucidal activity of ortho-phthalaldehyde solutions against hepatitis B and C viruses.
Ortho-phthalaldehyde (OPA), a high-level disinfectant alternative to...
16th April, 2008
Advanced Sterilization Products, Johnson and Johnson Company, Irvine, CA Am J Infect Control. 2008 Apr;36(3):223-6.
DOI Direct Link
Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile.
The preparation of the selective VEGF-R2 kinase inhibitor 10...
4th April, 2008
Johnson and Johnson Pharmaceutical Research & Development, L.L.C., 1000 J Org Chem. 2008 Feb 1;73(3):1121-3. Epub 2008 Jan 3.
DOI Direct Link
Predicting oral clearance in humans: how close can we get with allometry?
BACKGROUND: Oral clearance (CL/F) is an important pharmacokinetic...
19th March, 2008
ADME-TOX Department, Johnson and Johnson Pharmaceutical Research and Clin Pharmacokinet. 2008;47(1):35-45.
Quantitative, spatial resolution of the epigenetic field effect in prostate cancer.
BACKGROUND: Although a field effect in which transformed cells extend...
14th March, 2008
Veridex LLC, a Johnson and Johnson Company, Warren, New Jersey, USA. Prostate. 2008 Feb 1;68(2):152-60.
DOI Direct Link
An investigation of adhesion in drug-eluting stent layers.
An atomic force microscopy (AFM) method was developed to quantify the...
29th February, 2008
Cordis Corporation, A Johnson and Johnson Company, Welsh and McKean Roads, J Biomed Mater Res A. 2008 Oct;87(1):272-81.
DOI Direct Link
Determination of optical properties of superficial volumes of layered tissue phantoms.
Previously, we reported the design of a new diffusing probe that employs a...
27th February, 2008
Johnson and Johnson Consumer and Personal Products Worldwide, Skillman, NJ IEEE Trans Biomed Eng. 2008 Jan;55(1):335-9.
DOI Direct Link

«Johnson and Johnson

This page contained an extended Johnson and Johnson research listing. Click here to return to the Johnson and Johnson main Biocorporate entry.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.